Case number# PHEH2015US003310, is an initial report from consumer (patient spouse) via patient oriented 
program POP00002581 (Gilenya Go Program) received on 13 Feb 2015.
This report refers to a 29 year old male patient. Historical conditions and concomitant medication were not reported.
The patient received Gilenya (fingolimod) capsule 0.5 mg for the treatment of multiple sclerosis from 01 Oct 2014 at
a dose of 0.5 mg, QD (oral).
The patient was JCV positive (JC virus test positive). 
On 10 Nov 2014, the patient had elevated liver enzymes (details unspecified) (hepatic enzyme increased). Due to 
this, the patient was hospitalized on (b) (6)  The HCP (health care professional) had taken him off of Gilenya 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 35 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
because of elevated liver enzymes. The patient stopped the treatment with Gilenya on (b) (6)  The patient 
was discharged on (b) (6)  The patient would be put back on Gilenya once reduced liver enzymes.
The outcome of the events was reported as unknown. Causality of the events was not reported.